Spectrum Pharmaceuticals Announces Two Presentations at Upcoming ESMO TAT Virtual Congress 2021
Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced two presentations at the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021, scheduled for March 1-2, 2021. The oral presentation will discuss safety and efficacy data for poziotinib in EGFR/HER2 Exon 20 mutant non-small cell lung cancer, while another session will cover the effects of IGN002 in non-Hodgkin lymphoma. Access to these presentations will be available for ESMO members.
- Presentation of initial safety and efficacy data for poziotinib, which may advance its clinical profile.
- Participation in a reputable oncology conference, potentially enhancing visibility and credibility.
- No specific results or positive outcomes from clinical trials mentioned, leaving uncertainty about the drug's performance.
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021. The oral presentation will provide some initial safety and efficacy data for poziotinib from the twice daily dosing cohort. The meeting takes place on March 1 – 2, 2021. Details of the presentations are as follows:
Title: IGN002 (antiCD20-IFNα2b) intravenously administered tumor targeted delivery of IFNα2b and its effects in non-Hodgkin lymphoma
Speaker: Sribalaji Lakshmikanthan, Ph.D.
Session: Immunotherapy (ID 361)
Date and Time: March 1, 2021, 9:41 a.m. CET / 3:41 a.m. ET
Presentation Number: #20P (poster)
Title: Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer
Speaker: Adrian Sacher, M.D.
Session: Mini Oral Session (ID 17) Channel 1
Date and Time: March 2, 2021, 17:25 CET / 11:25 a.m. ET
Presentation Number: 36MO (mini-oral)
Access to the presentations is available to members of ESMO and can be found here: https://cslide.ctimeetingtech.com/tat2021/signin?back=%2Ftat2021%2Fattendee%2Fconfcal%2Fsession%2Fcalendar&module=attendee#signin
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.
Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc. and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.
© 2021 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005041/en/
FAQ
What is the significance of Spectrum Pharmaceuticals' presentations at the ESMO TAT 2021?
When will Spectrum Pharmaceuticals' presentations take place?
What type of data will be presented regarding poziotinib?
Who will speak at the Spectrum Pharmaceuticals presentations?
How can one access the presentations from the ESMO TAT 2021?
